Sacubitril/valsartan vs Enalapril in acute heart failure

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-08-17 03:45 GMT | Update On 2023-10-13 09:54 GMT

A recent study compared the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril (angiotensin-converting enzyme inhibitor [ACEI]) in patients with acute heart failure at 6-month follow-up. The study is published in Indian Heart Journal.

The study was a prospective, single centre, and observational study where patients with acute decompensated heart failure with reduced ejection fraction were included. Patients were divided in two groups: valsartan/sacubitril (ARNI) group and enalapril (ACEI). Patients were followed up for at least 6 months after administration of first dose and were evaluated for safety, efficacy, and tolerability of target drug.

A total of 200 patients were included in the present study,100 each in angiotensin receptor neprilysin inhibitor and angiotensin-converting enzyme inhibitor group. The mean maximum tolerated dose by population in angiotensin receptor neprilysin inhibitor group was 203.6 mg and 8.9 mg in angiotensin-converting enzyme inhibitor group. Re- admission for heart failure were seen significantly higher in angiotensin-converting enzyme inhibitor group than angiotensin receptor neprilysin inhibitor group. Parameters like ejection fraction, left ventricular end diastolic and systolic dimensions, 6 min walk test and Kansas City Cardiomyopathy Questionnaires (KCCQ) were also looked into.

Therefore, the researchers concluded that the angiotensin receptor neprilysin inhibitor study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to angiotensin-converting enzyme inhibitor group.

Reference:

Tahir Saleem Bhat, Imran Hafeez, Sobia Fatima Tak, "Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure e A prospective observational study" ;https://doi.org/10.1016/j.ihj.2022.04.003.

Full View

Article Source : Indian Heart Journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sacubitril/valsartan vs Enalapril in acute heart failure

Similar News

Weight Loss Drugs May Lower Risk of Heart Failure Hospitalization and Death by 40 Percent: Study

Is Your Mental Health Putting Your Heart at Risk? Study Sheds Light

No Benefit of Beta Blockers in Certain Heart Attack Patients: REBOOT Trial Finds

Study Reveals Potassium-Rich Foods May Lower Irregular Heartbeat Risk

Study Reveals Daily Intake of Five Mushrooms May Reduce Alzheimer's and Heart Disease Risk

Depression And Schizophrenia Double Heart Disease And Mortality Risks: Lancet Report

How Dangerous Is Irregular Sleep for Heart Failure Survivors? Study Finds Out

This Diet May Cut Risk of Cancer and Heart Disease Multimorbidity: Study Suggests